Patients with IDH mutant astrocytomas that are grade 2 (termed low grade or diffuse) or grade 3 (termed anaplastic, based on the presence of increased mitotic activity) and receiving optimal therapy have a median overall survival on the order of 8–12 years depending on the study [38]. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).